다비드화장품

비상장계속사업자

DAVID COSMETIC CO.,LTD.

이강욱

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

다비드화장품

Business Reg. No. 6358100917 · CEO 이강욱

I.Investment Overview

Target다비드화장품 (6358100917)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명다비드화장품
영문명DAVID COSMETIC CO.,LTD.
대표자이강욱
사업자등록번호6358100917
법인등록번호1201110927402
설립일2018.03.21

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW79.9202180.92022100.22023126.82024134.62025
영업이익100M KRW5.320218.120228.620239.9202412.72025
순이익100M KRW3.620215.82022520237202410.52025
Item20252024202320222021
자산총계165.3억원158.6억원146.2억원141.8억원144.5억원
부채총계104.1억원107.9억원102.5억원100.7억원113.2억원
자본총계61.2억원50.7억원43.7억원41.1억원31.3억원
매출액134.6억원126.8억원100.2억원80.9억원79.9억원
영업이익12.7억원9.9억원8.6억원8.1억원5.3억원
순이익10.5억원7억원5억원5.8억원3.6억원

VI.Financial Ratios

FY2025 basis

9.45%

영업이익률

7.83%

순이익률

6.38%

ROA

17.21%

ROE

169.93%

부채비율

37.05%

자기자본비율

VII.R&D Activity

Fields 보건의료 > 신약·의약품개발 · 화공 > 정밀화학

Keywords 사업화

YearProjectsPapersPatents
2026100
2023100

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

다비드화장품 투심보고서 | Alpha Lenz